Take-home messages
Orexin biology has fundamentally changed our understanding of narcolepsy. What was once viewed primarily as a disorder of excessive daytime sleepiness is now recognised as a complex neurological disease caused by loss of orexin signalling, with consequences extending across cognition, emotion, metabolism and quality of life.
Orexin receptor agonists represent the first genuinely disease-targeted treatment strategy for narcolepsy type 1. Rather than simply treating symptoms with daytime stimulants, night time sedatives or anticataplectic therapies, these drugs restore activity within the disrupted orexin pathway itself, producing improvements that many sleep specialists regard as unprecedented.
The field is entering a new era. Alongside exciting Phase 2 and Phase 3 clinical trial results, advances in biomarkers and understanding of disease mechanisms are increasing the possibility of earlier diagnosis, more physiological treatment, and eventually even disease-modifying approaches.
Narcolepsy really is one of the best bedtime stories of recent times.
The average UK medical student gets one or two hours of sleep teaching in a packed curriculum. As a medical student, I may have learnt about narcolepsy but in all honesty, I don’t remember, it was a curiosity and the cause was unknown. When I was a very junior neurology trainee in Newcastle, I do remember an enthusiastic neuroscientist explaining just how bizarre REM sleep was. It was the late 90s and the teacher was Dr Matthew Walker just before he left for Harvard (hopefully things went well for him out there).
By the time I completed neurology training, the biology of the sleep wake switches was far clearer. The accidental discovery of the orexin system made all of the clinical features of narcolepsy make sense. Without orexin, people toggle between sleep and wake with bits of dream like REM all over the night and day. The patients I treat are definitely better on their stimulants, their antidepressants and sometimes their sodium oxybate. But it is still a sleepier, dreamier life than mine with significant metabolic dysregulation particularly in children.
It has seemed a long time to wait for a safe orexinergic therapy. Year after year of the MS consultants returning from their conferences looking smug with yet another monoclonal antibody to use. Now they are here and the trial data looks better than every drug I currently use. Time will tell whether these drugs represent a key milestone in therapy, but those of us working in sleep clinics are excited about the next 5 years. – Kirstie Anderson
Across three complementary presentations, Markus Schmidt, Gert Jan Lammers and Ramin Khatani described how almost three decades of orexin research have transformed both the scientific understanding and clinical management of narcolepsy. Together, the talks charted a remarkable journey—from the discovery of the orexin (hypocretin) system in the late 1990s, through elucidation of the neurobiology of narcolepsy, to what many specialists now regard as one of the most significant therapeutic advances in sleep medicine for many years.
Professor Schmidt began by placing the field in historical context. The identification of orexin-producing neurons and the demonstration that their loss causes narcolepsy type 1 (NT1) fundamentally changed understanding of the disease. Rather than acting as a simple “wakefulness switch”, orexin was shown to stabilise multiple interconnected arousal systems throughout the brain. Loss of this stabilising influence explains not only excessive daytime sleepiness but also fragmented wakefulness, rapid transitions into REM sleep and cataplexy. His review highlighted how this biological framework has provided the foundation for every major therapeutic advance now emerging.
Importantly, the presentations emphasised that narcolepsy is far more than daytime sleepiness. Professor Lammers argued that clinicians have historically underestimated the broader impact of orexin deficiency. Patients frequently report impaired concentration, fatigue, reduced attention, mood disturbance and cognitive dysfunction, and these symptoms often contribute as much to disability as sleep attacks or cataplexy. Increasing evidence suggests these features arise directly from orexin deficiency rather than simply being due to poor sleep. This broader perspective represents an important shift in clinical thinking and reinforces the need to assess patients more holistically.
Both speakers also illustrated the expanding biological importance of the orexin system. Orexin influences multiple neurotransmitter pathways involved in arousal while interacting with systems regulating REM sleep, emotion, metabolism and motivation. This wider role may explain why people with narcolepsy often experience obesity, psychological symptoms and impaired cognitive performance alongside the classic sleep-related manifestations. Emerging work on biomarkers, including high-resolution mass spectrometry and the possibility of future blood-based assays, together with research into epigenetic silencing of orexin neurons, suggests that understanding of disease mechanisms continues to evolve. Although these approaches remain experimental, they raise the prospect of earlier diagnosis and even future disease-modifying therapies.
The strongest sense of excitement, however, centred on the emergence of selective orexin receptor-2 (OX2R) agonists. Professor Khatani described these agents as the first realistic opportunity to treat the underlying neurochemical deficit in NT1 rather than merely controlling individual symptoms. Unlike conventional therapies—which improve wakefulness or suppress cataplexy through indirect mechanisms—OX2R agonists activate the intact orexin receptors that remain after loss of orexin-producing neurons, effectively restoring signalling within the pathway that has failed. This represents a genuine conceptual shift from symptomatic treatment towards disease-targeted therapy.
| Sign up to the ACNR email newsletter here |
The clinical trial results presented explain why these developments have generated such enthusiasm within the sleep medicine community. Phase 3 studies of oveporexton (TAK-861) demonstrated improvements in objective wakefulness that approached normal values for many patients after 12 weeks of treatment. Subjective sleepiness also improved dramatically, with most participants achieving normal Epworth Sleepiness Scale scores. Equally impressive were the rapid and clinically meaningful reductions in cataplexy, with benefits emerging within weeks of treatment. These improvements exceed those generally seen with currently available symptomatic therapies and suggest that restoration of orexin signalling can normalise multiple aspects of disease simultaneously.
Perhaps even more striking was the breadth of benefit observed across the clinical trials. Improvements extended beyond wakefulness to encompass fatigue, sustained attention, cognition, emotional wellbeing, mobility, social participation and overall quality of life. These findings closely mirror Professor Lammers’ earlier argument that orexin deficiency affects multiple neurological functions, and they provide encouraging evidence that replacing orexin signalling may address many of these broader deficits rather than simply reducing sleepiness. Early Phase 2 data with additional compounds, including ALKS 2680, suggest that this therapeutic principle may extend across the emerging class of orexin receptor agonists, although further work is needed in narcolepsy type 2 and other hypersomnolence disorders.
Safety findings were also reassuring. The adverse effects observed to date have largely reflected predictable pharmacological actions, such as urinary frequency, urinary urgency and insomnia, rather than unexpected toxicity. Importantly, concerns surrounding liver toxicity seen with earlier generations of compounds have not emerged with the current agents, supporting optimism about their future clinical use while longer-term data continue to accumulate.
Taken together, these presentations conveyed a palpable sense that narcolepsy research has reached an inflection point. The discovery of orexin transformed understanding of disease biology; ongoing research continues to refine that understanding; and, for the first time, therapies are becoming available that directly address the underlying pathophysiology rather than simply compensating for its consequences. For sleep specialists, the Phase 3 results with orexin receptor agonists represent far more than another incremental advance—they signal the realistic possibility that patients with narcolepsy type 1 may soon receive treatments capable of restoring near-normal physiological function, marking the beginning of a new era in the management of this disabling neurological disorder.
| Sign up for our online community for neurology specialists |
AI was used in the summarising of this conference session, with expert commentary from Kirstie Anderson.
